Data show that C-reactive protein, LDL cholesterol, and lipoprotein(a) effectively predict heart disease in women.

A multicenter team led by the Brigham used patient data compiled from three large clinical trials to identify potential prognostic biomarkers that could be used to risk-stratify patients with atrial fibrillation based on their heart failure risk. First author Paul Haller, MD, PhD, discusses the study’s implications.

The V142I variant of the TTR gene, common among Black Americans, increases risks of cardiac amyloidosis, heart failure, and early mortality.

Researchers at Brigham and Women’s Hospital developed a novel aortic stenosis polygenic risk score (PRS) that incorporates more than five million genetic variants. They verified it was associated with aortic stenosis in two independent, very large populations.

By reviewing data from a long-term prospective study of U.S. women, researchers at Brigham and Women’s Hospital identified 12 biomarkers associated with premature CHD. They discuss the potential implications of biomarker screening and therapeutic strategies.

Direct oral anticoagulants (DOACs) are preferred to vitamin K antagonists for stroke prevention in atrial fibrillation, acute treatment and extended-duration secondary prevention of venous thromboembolism in most patients. However, DOACs may be less efficacious or safe compared to standard of care in other conditions.